📑 Extensive Product Profile: Understanding Canmab 440mg Injection

Canmab 440mg Injection contains Trastuzumab, an advanced recombinant DNA-derived humanized monoclonal antibody. Developed and manufactured to rigorous international standards by Biocon, it stands as a cornerstone targeted therapeutic agent deployed globally by oncologists to treat aggressive, mutation-specific epithelial tumors. The 440mg presentation is formulated as a multi-dose vial, offering clinical flexibility and cost-efficiency for extended treatment regimens.

1. Clinical Indications & Usage

Canmab 440mg is a multi-dose lyophilized targeted therapy globally indicated for:

• HER2-Overexpressing Breast Cancer:

• Adjuvant Treatment: Indicated for the treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing node-positive or node-negative breast cancer, implemented as part of a comprehensive treatment regimen alongside or following standard chemotherapy.

• Metastatic Treatment: Indicated in combination with paclitaxel or as a single agent for patients with HER2-positive metastatic breast cancer who have received one or more chemotherapy regimens for their metastatic disease.

• HER2-Overexpressing Metastatic Gastric Cancer: Indicated in combination with cisplatin and fluorouracil or capecitabine for the treatment of patients with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior anti-cancer therapy for metastatic disease.

2. Mechanism of Action: How Canmab Works

Canmab operates through a highly precise, multi-modal molecular pathway to target cancer cells selectively:

• Selective HER2 Receptor Binding: Trastuzumab binds with high affinity to extracellular domain IV of the human epidermal growth factor receptor 2 (HER2) protein. This protein is overexpressed on the surface of aggressive B-cell derived adenocarcinoma tissues.

• Inhibition of Intracellular Signaling: By binding to HER2, Canmab blocks ligand-independent HER2 homodimerization and heterodimerization. This shuts down downstream intracellular signaling cascades, specifically suppressing the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways that drive cell proliferation.

• Antibody-Dependent Cellular Cytotoxicity (ADCC): Canmab effectively "flags" the tumor cell for destruction. The Fc region of the bound antibody recruits host immune cells (such as natural killer cells), provoking an immune response that selectively destroys the heavily damaged cancer cell while sparing normal, healthy tissues with basal HER2 expression levels.

3. Administration and Dosing Guide

• Administration Route: Canmab 440mg is supplied as a sterile lyophilized powder. It must be reconstituted with the provided Bacteriostatic Water for Injection (BWFI) containing benzyl alcohol for multi-dose use, or Sterile Water for Injection (SWFI) for single-use. It must be diluted into a 0.9% Sodium Chloride infusion bag and administered exclusively as an Intravenous (IV) Infusion. Never give as an IV push or bolus.

• Initial Loading Dose: The standard clinical protocol initiates treatment with an initial loading dose of 4 mg/kg (for weekly schedules) or 8 mg/kg (for 3-weekly schedules) administered over a rigorous 90-minute IV infusion.

• Maintenance Schedule: If the initial infusion is well tolerated without immediate hypersensitivity reactions, subsequent maintenance doses (2 mg/kg weekly or 6 mg/kg every 3 weeks) can be administered over a shortened 30 to 60-minute window, managed strictly by the treating oncology nursing team.

⚠️ Safety, Side Effects, and Monitoring

Canmab 440mg is a potent antineoplastic biological agent requiring intensive clinical oversight:

• Cardiomyopathy (Cardiotoxicity): Canmab administration can result in subclinical and clinical cardiac failure, presenting as a significant decline in left ventricular ejection fraction (LVEF). Baseline and frequent periodic echocardiograms or MUGA scans are mandatory during treatment.

• Infusion-Related Reactions: Severe infusion reactions, including dyspnea, hypotension, wheezing, and bronchospasm, may occur during or immediately following administration. The infusion must be discontinued permanently for severe reactions.

• Embryo-Fetal Toxicity: Exposure to Trastuzumab during pregnancy can result in oligohydramnios (profoundly reduced amniotic fluid), manifesting as fatal pulmonary hypoplasia or skeletal abnormalities in the fetus.

• Common Side Effects: Fever, chills, nausea, vomiting, severe fatigue, headache, diarrhea, cough, altered taste, skin rashes, and a transient reduction in white blood cell counts.

📦 Storage and Handling Specifications

• Cold-Chain Framework: Store unopened Canmab 440mg vials consistently within a strict cold-chain infrastructure between 2°C to 8°C (36°F to 46°F) in a medical refrigerator. Do not freeze. Do not shake the reconstituted vial.

• Reconstituted Stability: Vials reconstituted with the provided Bacteriostatic Water for Injection (BWFI) are stable for up to 28 days when stored at 2°C to 8°C. If reconstituted with SWFI, the solution must be used immediately and any remaining portion discarded.

• Environmental Safeguards: Keep vials sealed inside their original manufacturer packaging to isolate the biological formulation from direct ambient UV light exposure.

📄 Regulatory and Compliance Documentation

PRIMECARE IMPEX simplifies international border clearance and institutional sourcing workflows by providing a comprehensive, audit-ready document pack with every consignment:

• Authentic Certificate of Analysis (COA) 

• Verified Batch Origin Ledger and commercial export documentation.

• GMP compliant manufacturing sourcing credentials.

💡 Why Choose PRIMECARE IMPEX?

Partnering with PRIMECARE IMPEX ensures secured, professional-grade cold-chain supply services for global hospital networks and wholesale distribution:

• Traceability.

• Regulatory Support

• Validated Cold-Chain Cargo

📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India

[GROUP OF PRIME CARE IMPEX PVT. LTD.]

Your Trusted Pharmaceutical Exporter, Bulk Supplier, and Global Distributor from India.

• 🌐 Corporate Website: www.medicineexporterfromindia.com

• 📧 Commercial Email: exports@ernestpharmaceuticals.com

• 📦 Business Type: Exporter | Bulk Supplier | Distributor

• 📲 Direct WhatsApp Line: +91 9673008130

• 🔗 Instant Chat Access: https://wa.me/919673008130